Charles Riv­er to work with Cu­ri­gin on gene ther­a­py treat­ment

Charles Riv­er Lab­o­ra­to­ries is ex­pand­ing its work in gene ther­a­py man­u­fac­tur­ing with its lat­est deal.

On Mon­day, Charles Riv­er an­nounced it is work­ing with the South Ko­re­an biotech Cu­ri­gin, which pro­duces on­colyt­ic ri­bonu­cle­ic acid in­ter­fer­ence (RNAi)-based gene ther­a­pies. The deal will see Charles Riv­er de­vel­op and man­u­fac­ture AAVs for Cu­ri­gin’s can­di­date CA102, a treat­ment for blad­der can­cer, for which it plans to sub­mit an IND to the FDA some­time next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER